Literature DB >> 12028052

Aplastic anaemia with 13q-: a benign subset of bone marrow failure responsive to immunosuppressive therapy.

Ken Ishiyama1, Masamitsu Karasawa, Shuichi Miyawaki, Yasunori Ueda, Masaaki Noda, Atsushi Wakita, Masakazu Sawanobori, Hirokazu Nagai, Shinji Nakao.   

Abstract

In an attempt to determine the pathological significance of a long arm deletion of chromosome 13 (13q-) in bone marrow failure syndrome, we reviewed the clinical records of nine patients who were initially diagnosed with aplastic anaemia due to bone marrow hypoplasia without dysplasia. Six patients responded to immunosuppressive therapy and the other three improved with steroids. None of the patients developed acute leukaemia (follow up: 54-129 months) and the estimated 5-year survival was 78%. These findings indicate that pancytopenia with 13q- represents bone marrow failure of a benign nature, similar to aplastic anaemia without karyotypic abnormalities, rather than preleukaemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028052     DOI: 10.1046/j.1365-2141.2002.03518.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation.

Authors:  Kohei Hosokawa; Takamasa Katagiri; Naomi Sugimori; Ken Ishiyama; Yumi Sasaki; Yu Seiki; Aiko Sato-Otsubo; Masashi Sanada; Seishi Ogawa; Shinji Nakao
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 3.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

4.  Comment to "Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation" Haematologica. 2012;97(12):1845-9.

Authors:  Andreas Holbro; Martine Jotterand; Jakob R Passweg; Andreas Buser; André Tichelli; Alicia Rovó
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

5.  Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

Authors:  Amy E DeZern; Marianna Zahurak; Heather Symons; Kenneth Cooke; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

Review 6.  Recent advances in understanding clonal haematopoiesis in aplastic anaemia.

Authors:  Natasha Stanley; Timothy S Olson; Daria V Babushok
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

7.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 8.  The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure.

Authors:  Siobán Keel; Amy Geddis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

9.  Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.

Authors:  Emma M Groarke; Bhavisha A Patel; Ruba Shalhoub; Fernanda Gutierrez-Rodrigues; Parth Desai; Harshraj Leuva; Yoshitaka Zaimoku; Casey Paton; Nina Spitofsky; Jennifer Lotter; Olga Rios; Richard W Childs; David J Young; Alina Dulau-Florea; Cynthia E Dunbar; Katherine R Calvo; Colin O Wu; Neal S Young
Journal:  Leukemia       Date:  2022-07-27       Impact factor: 12.883

Review 10.  Distinguishing constitutional from acquired bone marrow failure in the hematology clinic.

Authors:  Emma M Groarke; Neal S Young; Katherine R Calvo
Journal:  Best Pract Res Clin Haematol       Date:  2021-06-02       Impact factor: 3.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.